Rallybio Corporation
RLYB
$0.535
$0.0715.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 848.00K | 636.00K | 598.00K | 299.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 848.00K | 636.00K | 598.00K | 299.00K | -- |
| Cost of Revenue | 34.30M | 39.51M | 48.05M | 53.09M | 53.28M |
| Gross Profit | -33.45M | -38.87M | -47.45M | -52.80M | -53.28M |
| SG&A Expenses | 16.93M | 18.33M | 19.25M | 21.20M | 23.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.23M | 57.83M | 67.30M | 74.30M | 77.05M |
| Operating Income | -50.38M | -57.20M | -66.70M | -74.00M | -77.05M |
| Income Before Tax | -48.19M | -57.78M | -66.97M | -73.88M | -76.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.19 | -57.78 | -66.97 | -73.88 | -76.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.19M | -57.78M | -66.97M | -73.88M | -76.28M |
| EBIT | -50.38M | -57.20M | -66.70M | -74.00M | -77.05M |
| EBITDA | -50.26M | -57.07M | -66.56M | -73.86M | -76.90M |
| EPS Basic | -1.08 | -1.34 | -1.59 | -1.79 | -1.88 |
| Normalized Basic EPS | -0.68 | -0.79 | -0.94 | -1.07 | -1.12 |
| EPS Diluted | -1.08 | -1.34 | -1.59 | -1.79 | -1.88 |
| Normalized Diluted EPS | -0.68 | -0.79 | -0.94 | -1.07 | -1.12 |
| Average Basic Shares Outstanding | 178.16M | 174.16M | 170.13M | 166.07M | 162.31M |
| Average Diluted Shares Outstanding | 178.16M | 174.16M | 170.13M | 166.07M | 162.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |